Aduro Biotech Inc. (NASDAQ:ADRO) shares rose 3.4% on Thursday . The stock traded as high as $13.74 and last traded at $13.68, with a volume of 118,595 shares. The stock had previously closed at $13.23.

ADRO has been the topic of several recent analyst reports. FBR & Co reissued an “outperform” rating and set a $30.00 price objective on shares of Aduro Biotech in a research note on Monday, March 28th. Zacks Investment Research lowered shares of Aduro Biotech from a “hold” rating to a “sell” rating in a research note on Monday, July 18th. Roth Capital reissued a “buy” rating and set a $22.00 price objective on shares of Aduro Biotech in a research note on Monday, July 11th. Canaccord Genuity reissued a “buy” rating on shares of Aduro Biotech in a research note on Monday, May 16th. Finally, Leerink Swann reissued an “outperform” rating and set a $14.00 price objective (down previously from $48.00) on shares of Aduro Biotech in a research note on Tuesday, May 17th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Aduro Biotech has a consensus rating of “Hold” and an average target price of $24.17.

The company’s market cap is $904.55 million. The company has a 50 day moving average of $12.03 and a 200 day moving average of $13.89.

Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings data on Monday, May 2nd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.20. Analysts anticipate that Aduro Biotech Inc. will post ($1.24) earnings per share for the current fiscal year.

In other news, insider Thomas W. Dubensky sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $11.61, for a total value of $290,250.00. Following the completion of the transaction, the insider now owns 13,939 shares of the company’s stock, valued at $161,831.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

An institutional investor recently raised its position in Aduro Biotech stock. Jennison Associates LLC boosted its stake in shares of Aduro Biotech Inc. (NASDAQ:ADRO) by 9.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 855,338 shares of the company’s stock after buying an additional 74,073 shares during the period. Jennison Associates LLC owned approximately 1.35% of Aduro Biotech worth $24,069,000 as of its most recent SEC filing.

Aduro Biotech, Inc is a clinical-stage immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases. Its technologies are based on live, attenuated, double-deleted Listeria mononcytogenes (LADD) and cyclic dinucleotides (CDNs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.